Akebia Therapeutics, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging -16.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.03 | $-0.02 | +33.3% | Beat | Q2 FY26 call |
| Q1 FY26 | not reported | $-0.03 | not reported | not reported | |
| Q4 FY25 | $-0.03 | $-0.05 | -66.7% | Miss |
Back to AKBA overview · AKBA holders · AKBA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.